argenx Heads Into Q2 Print With Bears Firmly on the Sidelines

ARGX reports second-quarter results on July 23 with short sellers showing little conviction against the stock — and the lending market confirming that view almost completely.

Borrow demand is negligible. Short interest registers well below 1% of the free float, and availability is effectively unlimited, with over 13 million shares sitting unlent in the lending pool. The cost to borrow has nudged up roughly 6% over the past week to 0.70% — still firmly in "easy borrow" territory. That combination says the short community has no meaningful position to defend or cover heading into the print. The stock itself has been almost perfectly flat: down less than 1% on the week and off about 2% over the past month, closing at €760.20 on July 21.

The bull case rests squarely on efgartigimod. The FcRn inhibitor has been expanding across indications, and the most recent company update in mid-July reaffirmed strong mid-year pipeline momentum. Revenue growth has been running above 80% year-on-year, and the ORTEX momentum score has climbed meaningfully over recent months — the 50-day moving average crossed above the 200-day, and the stock was recently trading near its 52-week high. EPS surprise and momentum factor scores both rank around the 68th percentile of the universe, suggesting the company has been consistently outperforming consensus expectations. Bears have less structural ammunition than usual: the ORTEX short score of 43.6 is squarely mid-range and has barely moved across the past ten trading sessions, signalling no build-up of bearish flow. The valuation is genuinely rich — a price-to-earnings multiple near 27.6x — but that multiple has actually been compressing modestly over the past 30 days, not expanding, which limits the "crowded and expensive" narrative.

The institutional ownership picture adds further context. FMR and BlackRock together hold over 15% of shares, and Capital Research added 350,000 shares in the most recent reported quarter — a meaningful accumulation from one of the larger active managers in the register. Most other top holders have been steady or adding incrementally, suggesting no sign of distribution ahead of the print. Insider activity since early July has been limited to routine equity awards at zero cost — nothing that signals unusual conviction in either direction from management.

The earnings reaction history is worth noting. The most recent two prints both produced a day-one dip of roughly 2.5%, followed by a recovery that left the stock modestly higher five days out. That pattern — sell the news, then stabilise — reflects a stock where the headline number rarely disappoints but guidance language or trial updates can briefly unsettle the market.

Thursday's report will test whether efgartigimod's multi-indication expansion is translating into revenue at the pace the market has priced in, and whether the company's margin trajectory is convincing enough to justify a multiple that remains well above the sector average.